𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antagonists of bombesin/gastrin-releasing peptide as adjuncts to agonists of luteinizing hormone–releasing hormone in the treatment of experimental prostate cancer

✍ Scribed by Jacek Pinski; Gabor Halmos; Karoly Szepeshazi; Andrew V. Schally

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
752 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bone fractures associated with luteinizi
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
✍ Murphy F. Townsend; W. Holt Sanders; Robert O. Northway; Sam D. Graham Jr. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Background: Luteinizing hormone-releasing hormone agonists (lhrh-a) have become an established treatment for certain patients with prostate carcinoma. lhrh-a are known to decrease bone mineral density. the purpose of this study was to determine the risk of bone fracture in men receiving lhrh-a f

Luteinizing hormone-releasing hormone an
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
✍ Jungwirth, Andreas; Galvan, Georg; Pinski, Jacek; Halmos, Gabor; Szepeshazi, Kar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Background: Hormones like bombesin (bn)/gastrin-releasing peptide (grp) and luteinizing hormone-releasing hormone (lh-rh) and growth factors such as epidermal growth factor (egf) might be involved in the relapse of prostate cancer under androgen ablation therapy. interference with receptors for

Growth-inhibitory effects of luteinizing
Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice
✍ Donatella Dondi; Roberta M. Moretti; Marina Montagnani Marelli; Graziella Prates 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 131 KB 👁 2 views

Experiments have been performed to clarify whether LHRH agonists might decrease growth of hormone-unresponsive prostate cancer in vivo. Male nude mice were injected s.c. with the human androgen-independent prostate tumor DU 145 cells; osmotic minipumps releasing the LHRH agonist Zoladex (LHRH-A) for